Literature DB >> 9095174

Essential roles of the Fas ligand in the development of hepatitis.

T Kondo1, T Suda, H Fukuyama, M Adachi, S Nagata.   

Abstract

The Fas ligand (FasL) is expressed in activated T cells and induces apoptosis in Fas-bearing cells. A cytotoxic T lymphocyte (CTL) clone specific for hepatitis B surface antigen (HBsAg) causes an acute liver disease in HBsAg transgenic mice. Here we observed that the CTL clone killed hepatocytes expressing HBsAg in a Fas-dependent manner. Administration of the soluble form of Fas into HBsAg transgenic mice prevented the CTL-induced liver disease. In the second model, mice were primed with Propionibacterium acnes. A subsequent challenge with lipopolysaccharide (LPS) killed the mice by inducing liver injury. Neutralization of FasL rescued the mice from LPS-induced mortality, and Fas-null mice were resistant to LPS-induced mortality. These results suggest that FasL has an essential role in the development of hepatitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9095174     DOI: 10.1038/nm0497-409

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  94 in total

1.  Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis.

Authors:  M Tagashira; K Yamamoto; K Fujio; T Nagano; R Okamoto; N Ibuki; K Yabushita; S Matsumura; N Okano; T Tsuji
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

2.  Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection.

Authors:  J Ehrmann; D Galuszková; J Ehrmann; I Krc; V Jezdinská; B Vojtések; P G Murray; Z Koláo
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

Authors:  K B Elkon; C C Liu; J G Gall; J Trevejo; M W Marino; K A Abrahamsen; X Song; J L Zhou; L J Old; R G Crystal; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.

Authors:  C Bai; B Connolly; M L Metzker; C A Hilliard; X Liu; V Sandig; A Soderman; S M Galloway; Q Liu; C P Austin; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 5.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Fas-Fas ligand system as a possible mediator of spermatogenic cell apoptosis in human maturation-arrested testes.

Authors:  Jiro Eguchi; Takehiko Koji; Koichiro Nomata; Akira Yoshii; Masashi Shin; Hiroshi Kanetake
Journal:  Hum Cell       Date:  2002-03       Impact factor: 4.174

Review 7.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

8.  MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity.

Authors:  Wu Yang; John Guastella; Jin-Cheng Huang; Yan Wang; Li Zhang; Dong Xue; Minhtam Tran; Richard Woodward; Shailaja Kasibhatla; Ben Tseng; John Drewe; Sui Xiong Cai
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 9.  Apoptosis in animal models of virus-induced disease.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

10.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.